Etiology and Treatment of Hypogonadism in Adolescents

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 4, 2009, Pages 719-738

  Viswanathan, Vidhya ^a   Eugster, Erica A ^a  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Adolescents; Delayed puberty; Hypergonadotropic hypogonadism; Hypogonadotropic hypogonadism; Treatment

Indexed keywords

ASPARAGINASE; CELL NUCLEUS RECEPTOR; CHORIONIC GONADOTROPIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FOLLITROPIN; GONADORELIN; GONADOTROPIN; LEPTIN; LEPTIN RECEPTOR; LUTEINIZING HORMONE; MEDROXYPROGESTERONE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TRANSCRIPTION FACTOR; VINCRISTINE;

ADJUVANT THERAPY; ADOLESCENT; ADOLESCENT HEALTH; AMENORRHEA; ANDROGEN INSENSITIVITY SYNDROME; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM TUMOR; CONGENITAL ADRENAL HYPERPLASIA; DELAYED PUBERTY; DRUG DOSE INCREASE; EVENING DOSAGE; GALACTOSEMIA; GENE MUTATION; GONADAL DYSGENESIS; GROWTH RETARDATION; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; KALLMANN SYNDROME; KLINEFELTER SYNDROME; LYMPHATIC LEUKEMIA; MOLECULAR GENETICS; NONHODGKIN LYMPHOMA; NONHUMAN; PRADER WILLI SYNDROME; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RADIATION SICKNESS; REVIEW; RISK FACTOR; SKIN IRRITATION; TRAUMATIC BRAIN INJURY; TURNER SYNDROME; X CHROMOSOME ABERRATION;

ADOLESCENT; AUTOIMMUNE DISEASES; BRAIN INJURIES; CENTRAL NERVOUS SYSTEM DISEASES; DRUG THERAPY; GENETIC DISEASES, INBORN; HUMANS; HYPOGONADISM; RADIATION INJURIES; SYNDROME;

EID: 70449738614     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.08.004     Document Type: Review

References (116)

1. Boyar R., Finkelstein J., Roffwarg H., et al. Synchronization of augmented luteinizing hormone secretion with sleep during puberty. N Engl J Med 287 12 (1972) 582-586
2. Apter D., Butzow T.L., Laughlin G.A., et al. Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal patterns of circulating gonadotropins. J Clin Endocrinol Metab 76 4 (1993) 940-949
3. Sedlmeyer I.L., and Palmert M.R. Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab 87 4 (2002) 1613-1620
4. von Kalckreuth G., Haverkamp F., Kessler M., et al. Constitutional delay of growth and puberty: do they really reach their target height?. Horm Res 35 6 (1991) 222-225
5. Bergada I., and Bergada C. Long term treatment with low dose testosterone in constitutional delay of growth and puberty: effect on bone age maturation and pubertal progression. J Pediatr Endocrinol Metab 8 2 (1995) 117-122
6. Achermann J.C., Weiss J., Lee E.J., et al. Inherited disorders of the gonadotropin hormones. Mol Cell Endocrinol 179 1-2 (2001) 89-96
7. Kohler B., Lin L., Ferraz-de-Souza B., et al. Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46, XY patients with severe underandrogenization but without adrenal insufficiency. Hum Mutat 29 1 (2008) 59-64
8. Biason-Lauber A., and Schoenle E.J. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. Am J Hum Genet 67 6 (2000) 1563-1568
9. Muscatelli F., Strom T.M., Walker A.P., et al. Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature 372 6507 (1994) 672-676
10. Yang F., Hanaki K., Kinoshita T., et al. Late-onset adrenal hypoplasia congenita caused by a novel mutation of the DAX-1 gene. Eur J Pediatr 168 (2009) 329-331
11. Habiby R.L., Boepple P., Nachtigall L., et al. Adrenal hypoplasia congenita with hypogonadotropic hypogonadism: evidence that DAX-1 mutations lead to combined hypothalamic and pituitary defects in gonadotropin production. J Clin Invest 98 4 (1996) 1055-1062
12. Mantovani G., De Menis E., Borretta G., et al. DAX1 and X-linked adrenal hypoplasia congenita: clinical and molecular analysis in five patients. Eur J Endocrinol 154 5 (2006) 685-689
13. Franco B., Guioli S., Pragliola A., et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 353 6344 (1991) 529-536
14. Vogl T.J., Stemmler J., Heye B., et al. Kallman syndrome versus idiopathic hypogonadotropic hypogonadism at MR imaging. Radiology 191 1 (1994) 53-57
15. Oliveira L.M., Seminara S.B., Beranova M., et al. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab 86 4 (2001) 1532-1538
16. Sato N., Katsumata N., Kagami M., et al. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab 89 3 (2004) 1079-1088
17. Pitteloud N., Zhang C., Pignatelli D., et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A 104 44 (2007) 17447-17452
18. de Roux N., Young J., Misrahi M., et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 337 22 (1997) 1597-1602
19. de Roux N., and Milgrom E. Inherited disorders of GnRH and gonadotropin receptors. Mol Cell Endocrinol 179 1-2 (2001) 83-87
20. de Roux N., Genin E., Carel J.C., et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 100 19 (2003) 10972-10976
21. Raivio T., Falardeau J., Dwyer A., et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 357 9 (2007) 863-873
22. Pfaffle R.W., Blankenstein O., Wuller S., et al. Combined pituitary hormone deficiency: role of Pit-1 and Prop-1. Acta Paediatr Suppl 88 433 (1999) 33-41
23. Lazar L., Gat-Yablonski G., Kornreich L., et al. PROP-1 gene mutation (R120C) causing combined pituitary hormone deficiencies with variable clinical course in eight siblings of one Jewish Moroccan family. Horm Res 60 5 (2003) 227-231
24. Dasen J.S., Barbera J.P., Herman T.S., et al. Temporal regulation of a paired-like homeodomain repressor/TLE corepressor complex and a related activator is required for pituitary organogenesis. Genes Dev 15 23 (2001) 3193-3207
25. Dattani M.T., Martinez-Barbera J.P., Thomas P.Q., et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 19 2 (1998) 125-133
26. Haddad N.G., and Eugster E.A. Hypopituitarism and neurodevelopmental abnormalities in relation to central nervous system structural defects in children with optic nerve hypoplasia. J Pediatr Endocrinol Metab 18 9 (2005) 853-858
27. Pfaeffle R.W., Hunter C.S., Savage J.J., et al. Three novel missense mutations within the LHX4 gene are associated with variable pituitary hormone deficiencies. J Clin Endocrinol Metab 93 3 (2008) 1062-1071
28. Kelberman D., Rizzoti K., Avilion A., et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest 116 9 (2006) 2442-2455
29. Farooqi I.S., Matarese G., Lord G.M., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110 8 (2002) 1093-1103
30. Farooqi I.S., Wangensteen T., Collins S., et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 356 3 (2007) 237-247
31. Wharton R.H., and Loechner K.J. Genetic and clinical advances in Prader-Willi syndrome. Curr Opin Pediatr 8 6 (1996) 618-624
32. Jeffcoate W.J., Laurance B.M., Edwards C.R., et al. Endocrine function in the Prader-Willi syndrome. Clin Endocrinol (Oxf) 12 1 (1980) 81-89
33. Crino A., Schiaffini R., Ciampalini P., et al. Hypogonadism and pubertal development in Prader-Willi syndrome. Eur J Pediatr 162 5 (2003) 327-333
34. Schulze A., Mogensen H., Hamborg-Petersen B., et al. Fertility in Prader-Willi syndrome: a case report with Angelman syndrome in the offspring. Acta Paediatr 90 4 (2001) 455-459
35. Akefeldt A., Tornhage C.J., and Gillberg C. A woman with Prader-Willi syndrome gives birth to a healthy baby girl. Dev Med Child Neurol 41 11 (1999) 789-790
36. Morton M.V., and Wehman P. Psychosocial and emotional sequelae of individuals with traumatic brain injury: a literature review and recommendations. Brain Inj 9 1 (1995) 81-92
37. Kelly D.F., Gonzalo I.T., Cohan P., et al. Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. J Neurosurg 93 5 (2000) 743-752
38. Lieberman S.A., Oberoi A.L., Gilkison C.R., et al. Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. J Clin Endocrinol Metab 86 6 (2001) 2752-2756
39. Benvenga S., Campenni A., Ruggeri R.M., et al. Clinical review 113: hypopituitarism secondary to head trauma. J Clin Endocrinol Metab 85 4 (2000) 1353-1361
40. Tanriverdi F., Senyurek H., Unluhizarci K., et al. High risk of hypopituitarism after traumatic brain injury: a prospective investigation of anterior pituitary function in the acute phase and 12 months after trauma. J Clin Endocrinol Metab 91 6 (2006) 2105-2111
41. Merchant T.E., Williams T., Smith J.M., et al. Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int J Radiat Oncol Biol Phys 54 1 (2002) 45-50
42. Gonc E.N., Yordam N., Ozon A., et al. Endocrinological outcome of different treatment options in children with craniopharyngioma: a retrospective analysis of 66 cases. Pediatr Neurosurg 40 3 (2004) 112-119
43. Mills J.L., Fears T.R., Robison L.L., et al. Menarche in a cohort of 188 long-term survivors of acute lymphoblastic leukemia. J Pediatr 131 4 (1997) 598-602
44. Constine L.S., Woolf P.D., Cann D., et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 328 2 (1993) 87-94
45. Rappaport R., Brauner R., Czernichow P., et al. Effect of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. J Clin Endocrinol Metab 54 6 (1982) 1164-1168
46. Nandagopal R., Laverdiere C., Mulrooney D., et al. Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res 69 2 (2008) 65-74
47. Chan J.L., and Mantzoros C.S. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 366 9479 (2005) 74-85
48. Welt C.K., Chan J.L., Bullen J., et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351 10 (2004) 987-997
49. Nielsen J., and Wohlert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet 87 1 (1991) 81-83
50. Bondy C.A. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 92 1 (2007) 10-25
51. Pasquino A.M., Passeri F., Pucarelli I., et al. Spontaneous pubertal development in Turner's syndrome. Italian Study Group for Turner's Syndrome. J Clin Endocrinol Metab 82 6 (1997) 1810-1813
52. Hovatta O. Pregnancies in women with Turner's syndrome. Ann Med 31 2 (1999) 106-110
53. Fechner P.Y., Davenport M.L., Qualy R.L., et al. Differences in follicle-stimulating hormone secretion between 45, X monosomy Turner syndrome and 45, X/46, XX mosaicism are evident at an early age. J Clin Endocrinol Metab 91 12 (2006) 4896-4902
54. Bojesen A., Juul S., and Gravholt C.H. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 88 2 (2003) 622-626
55. Abulhasan S.J., Tayel S.M., and al-Awadi S.A. Mosaic Turner syndrome: cytogenetics versus FISH. Ann Hum Genet 63 Pt 3 (1999) 199-206
56. Rizzolio F., Bione S., Sala C., et al. Chromosomal rearrangements in Xq and premature ovarian failure: mapping of 25 new cases and review of the literature. Hum Reprod 21 6 (2006) 1477-1483
57. Linden M.G., Bender B.G., Harmon R.J., et al. 47, XXX: what is the prognosis?. Pediatrics 82 4 (1988) 619-630
58. Lin H.J., Ndiforchu F., and Patell S. Exstrophy of the cloaca in a 47, XXX child: review of genitourinary malformations in triple-X patients. Am J Med Genet 45 6 (1993) 761-763
59. Holland C.M. 47, XXX in an adolescent with premature ovarian failure and autoimmune disease. J Pediatr Adolesc Gynecol 14 2 (2001) 77-80
60. Matthews C.H., Borgato S., Beck-Peccoz P., et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet 5 1 (1993) 83-86
61. Layman L.C., Lee E.J., Peak D.B., et al. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene. N Engl J Med 337 9 (1997) 607-611
62. Lindstedt G., Nystrom E., Matthews C., et al. Follitropin (FSH) deficiency in an infertile male due to FSHbeta gene mutation. A syndrome of normal puberty and virilization but underdeveloped testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. Clin Chem Lab Med 36 8 (1998) 663-665
63. Weiss J., Axelrod L., Whitcomb R.W., et al. Hypogonadism caused by a single amino acid substitution in the beta subunit of luteinizing hormone. N Engl J Med 326 3 (1992) 179-183
64. Furui K., Suganuma N., Tsukahara S., et al. Identification of two point mutations in the gene coding luteinizing hormone (LH) beta-subunit, associated with immunologically anomalous LH variants. J Clin Endocrinol Metab 78 1 (1994) 107-113
65. Kremer H., Kraaij R., Toledo S.P., et al. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nat Genet 9 2 (1995) 160-164
66. Latronico A.C., Anasti J., Arnhold I.J., et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 334 8 (1996) 507-512
67. Arnhold I.J., Latronico A.C., Batista M.C., et al. Clinical features of women with resistance to luteinizing hormone. Clin Endocrinol (Oxf) 51 6 (1999) 701-707
68. Aittomaki K. The genetics of XX gonadal dysgenesis. Am J Hum Genet 54 5 (1994) 844-851
69. de Zegher F., and Jaeken J. Endocrinology of the carbohydrate-deficient glycoprotein syndrome type 1 from birth through adolescence. Pediatr Res 37 4 Pt 1 (1995) 395-401
70. Gelfand I.M., Eugster E.A., and DiMeglio L.A. Presentation and clinical progression of pseudohypoparathyroidism with multi-hormone resistance and Albright hereditary osteodystrophy: a case series. J Pediatr 149 6 (2006) 877-880
71. Lee P.A., Houk C.P., Ahmed S.F., et al. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 118 2 (2006) e488-e500
72. Michala L., Goswami D., Creighton S.M., et al. Swyer syndrome: presentation and outcomes. BJOG 115 6 (May 2008) 737-741
73. Zielinska D., Zajaczek S., and Rzepka-Gorska I. Tumors of dysgenetic gonads in Swyer syndrome. J Pediatr Surg 42 10 (2007) 1721-1724
74. Oakes M.B., Eyvazzadeh A.D., Quint E., et al. Complete androgen insensitivity syndrome-a review. J Pediatr Adolesc Gynecol 21 6 (2008) 305-310
75. Sarpel U., Palmer S.K., and Dolgin S.E. The incidence of complete androgen insensitivity in girls with inguinal hernias and assessment of screening by vaginal length measurement. J Pediatr Surg 40 1 (2005) 133-136 [discussion: 136-7]
76. Costa-Santos M., Kater C.E., and Auchus R.J. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 89 1 (2004) 49-60
77. Yang J., Cui B., Sun S., et al. Phenotype-genotype correlation in eight Chinese 17alpha-hydroxylase/17,20 lyase-deficiency patients with five novel mutations of CYP17A1 gene. J Clin Endocrinol Metab 91 9 (2006) 3619-3625
78. al Kandari H., Katsumata N., Alexander S., et al. Homozygous mutation of P450 side-chain cleavage enzyme gene (CYP11A1) in 46, XY patient with adrenal insufficiency, complete sex reversal, and agenesis of corpus callosum. J Clin Endocrinol Metab 91 8 (2006) 2821-2826
79. Baker B.Y., Lin L., Kim C.J., et al. Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 91 12 (2006) 4781-4785
80. Fujieda K., Tajima T., Nakae J., et al. Spontaneous puberty in 46, XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. J Clin Invest 99 6 (1997) 1265-1271
81. Kaufman F.R., Kogut M.D., Donnell G.N., et al. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 304 17 (1981) 994-998
82. Prestoz L.L., Couto A.S., Shin Y.S., et al. Altered follicle stimulating hormone isoforms in female galactosaemia patients. Eur J Pediatr 156 2 (1997) 116-120
83. Smith N.M., Byard R.W., and Bourne A.J. Testicular regression syndrome-a pathological study of 77 cases. Histopathology 19 3 (1991) 269-272
84. Law H., Mushtaq I., Wingrove K., et al. Histopathological features of testicular regression syndrome: relation to patient age and implications for management. Fetal Pediatr Pathol 25 2 (2006) 119-129
85. Imbeaud S., Rey R., Berta P., et al. Testicular degeneration in three patients with the persistent mullerian duct syndrome. Eur J Pediatr 154 3 (1995) 187-190
86. Vinci G., Anjot M.N., Trivin C., et al. An analysis of the genetic factors involved in testicular descent in a cohort of 14 male patients with anorchia. J Clin Endocrinol Metab 89 12 (2004) 6282-6285
87. Wallace W.H., Thomson A.B., and Kelsey T.W. The radiosensitivity of the human oocyte. Hum Reprod 18 1 (2003) 117-121
88. Larsen E.C., Muller J., Schmiegelow K., et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 88 11 (2003) 5307-5314
89. Lopez Andreu J.A., Fernandez P.J., Ferris i Tortajada J., et al. Persistent altered spermatogenesis in long-term childhood cancer survivors. Pediatr Hematol Oncol 17 1 (2000) 21-30
90. Shalet S.M., Tsatsoulis A., Whitehead E., et al. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J Endocrinol 120 1 (1989) 161-165
91. Steffens M., Beauloye V., Brichard B., et al. Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf) 69 5 (2008) 819-827
92. Rahhal S.N., and Eugster E.A. Unexpected recovery of ovarian function many years after bone marrow transplantation. J Pediatr 152 2 (2008) 289-290
93. Meacham L.R., Ghim T.T., Crocker I.R., et al. Systematic approach for detection of endocrine disorders in children treated for brain tumors. Med Pediatr Oncol 29 2 (1997) 86-91
94. Schatz D.A., and Winter W.E. Autoimmune polyglandular syndrome. II: clinical syndrome and treatment. Endocrinol Metab Clin North Am 31 2 (2002) 339-352
95. Wolff A.S., Erichsen M.M., Meager A., et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 92 2 (2007) 595-603
96. Ahonen P., Miettinen A., and Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 64 3 (1987) 494-500
97. Uibo R., Aavik E., Peterson P., et al. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J Clin Endocrinol Metab 78 2 (1994) 323-328
98. Hoek A., Schoemaker J., and Drexhage H.A. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 18 1 (1997) 107-134
99. Buzi F., Badolato R., Mazza C., et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome: time to review diagnostic criteria?. J Clin Endocrinol Metab 88 7 (2003) 3146-3148
100. Perniola R., Falorni A., Clemente M.G., et al. Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Eur J Endocrinol 143 4 (2000) 497-503
101. Sinisi A.A., D'Apuzzo A., Pasquali D., et al. Antisperm antibodies in prepubertal boys treated with chemotherapy for malignant or non-malignant diseases and in boys with genital tract abnormalities. Int J Androl 20 1 (1997) 23-28
102. Goodpasture J.C., Ghai K., Cara J.F., et al. Potential of gonadotropin-releasing hormone agonists in the diagnosis of pubertal disorders in girls. Clin Obstet Gynecol 36 3 (1993) 773-785
103. Rosenfield R.L., Perovic N., Devine N., et al. Optimizing estrogen replacement treatment in Turner syndrome. Pediatrics 102 2 Pt 3 (1998) 486-488
104. Donaldson M.D., Gault E.J., Tan K.W., et al. Optimising management in Turner syndrome: from infancy to adult transfer. Arch Dis Child 91 6 (2006) 513-520
105. Mauras N., Shulman D., Hsiang H.Y., et al. Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with turner syndrome. J Clin Endocrinol Metab 92 11 (2007) 4154-4160
106. Ankarberg-Lindgren C., Elfving M., Wikland K.A., et al. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab 86 7 (2001) 3039-3044
107. Chetkowski R.J., Meldrum D.R., Steingold K.A., et al. Biologic effects of transdermal estradiol. N Engl J Med 314 25 (1986) 1615-1620
108. Nabhan Z.M., DiMeglio L.A., Qi R., et al. Oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. J Clin Endocrinol Metab 94 6 (2009) 2009-2014
109. Piippo S., Lenko H., Kainulainen P., et al. Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. J Clin Endocrinol Metab 89 7 (2004) 3241-3247
110. Richman R.A., and Kirsch L.R. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med 319 24 (1988) 1563-1567
111. Soliman A.T., Khadir M.M., and Asfour M. Testosterone treatment in adolescent boys with constitutional delay of growth and development. Metabolism 44 8 (1995) 1013-1015
112. Arslanian S., and Suprasongsin C. Testosterone treatment in adolescents with delayed puberty: changes in body composition, protein, fat, and glucose metabolism. J Clin Endocrinol Metab 82 10 (1997) 3213-3220
113. Rogol A.D. Pubertal androgen therapy in boys. Pediatr Endocrinol Rev 2 3 (2005) 383-390
114. Kassmann K., Rappaport R., and Broyer M. The short-term effect of testosterone on growth in boys on hemodialysis. Clin Nephrol 37 3 (1992) 148-154
115. Mayo A., Macintyre H., Wallace A.M., et al. Transdermal testosterone application: pharmacokinetics and effects on pubertal status, short-term growth, and bone turnover. J Clin Endocrinol Metab 89 2 (2004) 681-687
116. Eiholzer U., Grieser J., Schlumpf M., et al. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. Horm Res 68 4 (2007) 178-184